Antisense compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment of diseases associated with expression of Interleukin 12 p35 subunit are provided.
Claims What is claimed is: 1. A compound 8 to 50 nucleobases in length targeted to nucleobases 1 through 9 or nucleobases 61 through 85 of a 5'-untranslated region, nucleobases 148 through 167, nucleobases 183 through 201, nucleobases 230 through 249, nucleobases 255 through 274, nucleobases 282 through 304, nucleobases 332 through 351, nucleobases 356 through 409, nucleobases 435 through 521, nucleobases 542 through 572, nucleobases 587 through 705, nucleobases 727 through 756, nucleobases 790 through 823, or nucleobases 828 through 847 of a coding region, a stop codon region, nucleobases 877 through 896, nucleobases 908 through 958, nucleobases 987 through 1006, nucleobases 1035 through 1060, nucleobases 1066 through 1092, nucleobases 1099 through 1177, nucleobases 1194 through 1231, or nucleobases 1284 through 1303 of a 3'-untranslated region of a nucleic acid molecule encoding human lnterleukin 12 p35 subunit (SEQ ID NO: 3), or nucleobases 1597-1698 of a coding region of a nucleic acid molecule encoding Interleukin 12 p35 subunit (SEQ ID NO: 10), wherein said compound specifically hybridizes with one of said regions and inhibits the expression of human Interleukin 12 p35 subunit. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 11, 13, 14, 16, 17, 20, 21, 22, 23, 26, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 66, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 82, 85, 87 or 88 which inhibits the expression of Interleukin 12 p35 subunit. 4. The compound of claim 2 wherein the antisense oligonucleoticle comprises at least one modified internucleosicle linkage. 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage. 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11, further comprising a colloidal dispersion system. 13. The composition of claim 11, wherein the compound is an antisense oligonucleotide. 14. A method of inhibiting the expression of human Interleukin 12 p35 subunit in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of human Interleukin 12 p35 subunit is inhibited. 15. The compound of claim 3 which is an antisense oligonucleotide. 16. The compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The compound of claim 16, wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The compound of claim 18, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The compound of claim 20, wherein the modified nucleobase is a 5-methylcytosine. 22. The compound of claim 15, wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 24. The composition of claim 23, further comprising a colloidal dispersion system. 25. The composition of claim 23, wherein the antisense compound is an antisense oligonucleotide. 26. A method of inhibiting the expression of interleukin 12 p35 subunit in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 3 so that expression of inhibiting the expression of Interleukin 12 p35 subunit is inhibited. 